Long-term results for children with high-risk neuroblastoma treated on a randomized trial of myeloablative therapy followed by 13-cis-retinoic acid: a children's oncology group study - Test2 - elhamkhani - TriplyDB

Long-term results for children with high-risk neuroblastoma treated on a randomized trial of myeloablative therapy followed by 13-cis-retinoic acid: a children's oncology group study

Long-term results for children with high-risk neuroblastoma treated on a randomized trial of myeloablative therapy followed by 13-cis-retinoic acid: a children's oncology group study

http://www.wikidata.org/entity/Q24658339

about

Vitamin A and retinoid derivatives for lung cancer: a systematic review and meta analysis Retinoic acid post consolidation therapy for high-risk neuroblastoma patients treated with autologous hematopoietic stem cell transplantation High-dose chemotherapy and autologous haematopoietic stem cell rescue for children with high-risk neuroblastoma Rapid COJEC versus standard induction therapies for high-risk neuroblastoma Rapid COJEC versus standard induction therapies for high-risk neuroblastoma High-dose chemotherapy and autologous haematopoietic stem cell rescue for children with high-risk neuroblastoma Iodine-131-meta-iodobenzylguanidine therapy for patients with high-risk neuroblastoma High-dose chemotherapy and autologous haematopoietic stem cell rescue for children with high-risk neuroblastoma TRIM16 acts as a tumour suppressor by inhibitory effects on cytoplasmic vimentin and nuclear E2F1 in neuroblastoma cells Anti-GD2 antibody with GM-CSF, interleukin-2, and isotretinoin for neuroblastoma Role of Retinoic Acid-Metabolizing Cytochrome P450s, CYP26, in Inflammation and Cancer Natural killer cells and neuroblastoma: tumor recognition, escape mechanisms, and possible novel immunotherapeutic approaches Neuroblastoma: issues in transplantation Nuclear GRP75 binds retinoic acid receptors to promote neuronal differentiation of neuroblastoma CDK Inhibitors Roscovitine and CR8 Trigger Mcl-1 Down-Regulation and Apoptotic Cell Death in Neuroblastoma Cells Hematopoetic stem cell transplantation in children TL-118 and gemcitabine drug combination display therapeutic efficacy in a MYCN amplified orthotopic neuroblastoma murine model--evaluation by MRI Temporal proteomics of NGF-TrkA signaling identifies an inhibitory role for the E3 ligase Cbl-b in neuroblastoma cell differentiation Overview and recent advances in the treatment of neuroblastoma.Cytotoxicity of activated natural killer cells against pediatric solid tumors.Adaptive dosing approaches to the individualization of 13-cis-retinoic acid (isotretinoin) treatment for children with high-risk neuroblastoma.Metastatic neuroblastoma cancer stem cells exhibit flexible plasticity and adaptive stemness signaling.Impact of Whole-Body Radiation Dose on Response and Toxicity in Patients With Neuroblastoma After Therapy With 131 I-Metaiodobenzylguanidine (MIBG).Phase I study of bortezomib in combination with irinotecan in patients with relapsed/refractory high-risk neuroblastoma.Integrating cell-based and clinical genome-wide studies to identify genetic variants contributing to treatment failure in neuroblastoma patients Extracellular matrix rigidity modulates neuroblastoma cell differentiation and N-myc expression A single center clinical analysis of children with high-risk neuroblastoma.Treatment of atypical central neurocytoma in a child with high dose chemotherapy and autologous stem cell rescue.Stromal heparan sulfate differentiates neuroblasts to suppress neuroblastoma growth.Outcome for children with metastatic solid tumors over the last four decades Neuroblastoma in Africa: A Survey by the Franco-African Pediatric Oncology Group.Outcomes for children and adolescents with cancer: challenges for the twenty-first century.YAP promotes tumorigenesis and cisplatin resistance in neuroblastoma Radiation therapy as part of local control of metastatic neuroblastoma: the St Jude Children's Research Hospital experience.An integrated proteomic approach to identifying circulating biomarkers in high-risk neuroblastoma and their potential in relapse monitoring Peripheral blood stem cell support for multiple cycles of dose intensive induction therapy is feasible with little risk of tumor contamination in advanced stage neuroblastoma: a report from the Childrens Oncology Group NF1 is a tumor suppressor in neuroblastoma that determines retinoic acid response and disease outcome.Prevalence of advanced bone age in a cohort of patients who received cis-retinoic acid for high-risk neuroblastoma.Targeted isotretinoin in neuroblastoma: kinetics, genetics, or absorption.Synergistic activity of fenretinide and the Bcl-2 family protein inhibitor ABT-737 against human neuroblastoma.

P2860

Q21089955-41F7A89D-3729-43C1-828E-53E3B4CE755C Q24186451-1DC2B97B-D859-4E9F-9197-1C69A8D11D29 Q24186636-216CC446-20A3-4BC3-A750-E353BD60EE96 Q24187922-B4F3C687-A854-488B-9794-BE802C0F16B1 Q24197871-1A0356CD-F609-4936-A84F-E6840057B20A Q24200296-9108959D-F489-4F9D-9BAE-D94A6856FE8A Q24201280-CE533BF6-C7AB-4862-9801-F81ED2106374 Q24235309-E182C843-0E6B-457E-9648-C0F92F08E2CB Q24297046-A2B1FCF3-6D41-4AF3-9C04-A34457473142 Q24602657-B6DAB217-A653-4132-9DE1-83010273F03E Q26800202-5DBB4B62-1943-4927-BB7D-BFE21869E454 Q26825652-68FE634A-AB7D-4E87-BC5A-CCE5925CEA5D Q27008197-1F1A3412-F904-4F52-AA38-1EDCF78150B2 Q27316571-D8413CF6-F4D9-4EC4-8E31-FA0A886431DF Q27670943-9FA5CF89-7FFD-43AB-9A80-9F969AD2CB09 Q28088687-7032B3F8-5474-4800-BF84-2E61BB4110A3 Q28540575-CD9B7574-9884-41CF-8235-E90A30FED0FF Q30002320-E0201B02-4FF6-4299-89E2-37B098708738 Q30238693-094E861E-314E-47D8-8FBD-31796551FE32 Q30503995-DE53812A-8E3B-488B-A851-1E9BAAC7899C Q30532640-41402422-38FC-4305-BA29-63D11CF981AB Q30639268-5820CE4E-D124-4C2E-8FD7-A36308FFA977 Q33427090-8BCD793E-8662-4750-8DD7-32181D466BA5 Q33441292-2B70DA19-5BEC-4D68-A889-0C757282EEA3 Q33645629-3CC72F4A-FDF3-4046-B80D-39E4853B5817 Q33702245-4C94DD28-3D06-407C-BD2D-FD06DF0B36FE Q33728327-E1AF4F55-2C49-40A2-990F-29391D7F6894 Q33805151-F0F4D21A-1318-4B22-BC5D-BD6917AABAF3 Q33808326-249763B6-A1FA-453B-AE6E-5845F7A49F16 Q33863587-90018D02-62D5-4DEE-BB14-7926D535874E Q33872797-196AE3C4-8BCB-499F-9DC2-0333291DEE3E Q33897659-E79C8B2D-DCC5-4CF7-BD1C-093240BA3C22 Q33913845-EE5ECF1E-903D-4C90-B78D-FB5E3653B547 Q33964937-0FD9E2CD-6773-4F1C-AD59-93BF28DFCF27 Q33990542-90034765-0721-4A3F-A540-B1905BD69397 Q33999779-75EDE720-14C4-4079-BFB8-18A95C54B8D3 Q34031980-681621F8-B5CB-4301-8F70-F181F85318BF Q34149469-CDEEF579-8A10-493A-A8DE-86622263E708 Q34315331-CF7C741B-BD46-495C-AFDF-5D905AA3E1AF Q34323880-DE2E081B-0A5A-4591-A6F4-9B46184BE0E5

P2860

Long-term results for children with high-risk neuroblastoma treated on a randomized trial of myeloablative therapy followed by 13-cis-retinoic acid: a children's oncology group study

http://www.wikidata.org/entity/Q24658339

description

2009 nî lūn-bûn

@nan

2009 թուականի Մարտին հրատարակուած գիտական յօդուած

@hyw

2009 թվականի մարտին հրատարակված գիտական հոդված

@hy

2009年の論文

@ja

2009年論文

@yue

2009年論文

@zh-hant

2009年論文

@zh-hk

2009年論文

@zh-mo

2009年論文

@zh-tw

2009年论文

@wuu

name

Long-term results for children ...... hildren's oncology group study

@ast

Long-term results for children ...... hildren's oncology group study

@en

Long-term results for children ...... hildren's oncology group study

@nl

type

label

Long-term results for children ...... hildren's oncology group study

@ast

Long-term results for children ...... hildren's oncology group study

@en

Long-term results for children ...... hildren's oncology group study

@nl

prefLabel

Long-term results for children ...... hildren's oncology group study

@ast

Long-term results for children ...... hildren's oncology group study

@en

Long-term results for children ...... hildren's oncology group study

@nl

P1433

Q24658339-8A341432-21DE-4015-BAAE-2BFBC69E8A0F

P1476

Q24658339-0E2C5C9C-5822-43B1-B137-B5F52AA71FF2

P2093

Q24658339-05D0B5B3-D5E6-4297-A462-3BA76E0F5EF1

Q24658339-1407DD61-20D2-43D2-A718-467DDCB5E050

Q24658339-36FB884A-CD74-45AB-A2D7-563846D4424A

Q24658339-60DA21A0-991E-4D72-A509-9355ECFAE9DC

Q24658339-71E1E320-69E9-4D19-83F5-5C6FD1C7772B

Q24658339-8C1F1316-406F-41F0-9832-120F729CC2B0

Q24658339-9ED2BD10-3B7D-49DC-8488-1B2998397BC6

Q24658339-D0130AD3-7E9E-4E43-940B-BAC81F989FDF

P2860

Q24658339-1D5DB5A8-93AF-4416-89E6-06413BE1A215

Q24658339-39B3380E-B3D2-4020-9AAC-BF8870256D8C

Q24658339-486AACDC-8FB9-405D-A010-196EBD2ECA47

Q24658339-4B932AC5-3174-4F6F-8E14-71609E73E2DC

Q24658339-5136F13F-F6AA-4788-B493-B2F270E2E86B

Q24658339-5EAA9CB2-5FD8-4E2A-9CE9-B498F1C5098F

Q24658339-75157C4B-C8EC-48D0-A43C-DF4B23A6C1B3

Q24658339-7A9798CF-1520-4792-8B90-D90C493FFB11

Q24658339-7B53ADC5-F7A0-477F-A786-7F9BF35FC3F2

Q24658339-7F8ACBB4-367C-41D0-ABEE-15E3CC9517EC

P304

Q24658339-055791BF-6B2C-4D15-AEA0-47026B87E3AC

P31

Q24658339-4A5AF9BF-1C7B-46D8-AC92-80D19EC37635

P3181

Q24658339-6159AE53-EFA6-4114-AF3E-50DA044C8E72

P356

Q24658339-77B0B9A0-FBE9-4EF4-87CE-A11E47A27DCD

P407

Q24658339-5E807041-C95C-4ADF-8113-0B9C4E93676B

P433

Q24658339-9722CD91-42F1-44FC-867A-7BBC539C7562

P478

Q24658339-B98A47B7-689E-4AD9-B446-BEAD89D17FBD

P50

Q24658339-2FADA705-11EE-4934-82F6-655CFB448C0C

P577

Q24658339-F7871D2C-CD9D-4F7A-A34A-76842FFEB863

P698

Q24658339-3DA22E7B-2876-4D40-8D2C-C07CD8928796

P932

Q24658339-F5D45F94-3C70-4834-9394-7A9A44B6FACF

P3181

P356

JCO.2007.13.8925

P1433

Journal of Clinical Oncology

P1476

Long-term results for children ...... hildren's oncology group study

@en

P2093

Daphne Haas-Kogan

http://www.w3.org/2001/XMLSchema#string

E Stanton Adkins

http://www.w3.org/2001/XMLSchema#string

Hiroyuki Shimada

http://www.w3.org/2001/XMLSchema#string

Judith G Villablanca

http://www.w3.org/2001/XMLSchema#string

Katherine K Matthay

http://www.w3.org/2001/XMLSchema#string

Robert B Gerbing

http://www.w3.org/2001/XMLSchema#string

Robert C Seeger

http://www.w3.org/2001/XMLSchema#string

Wendy B London

http://www.w3.org/2001/XMLSchema#string

P2860

Design and analysis of randomized clinical trials requiring prolonged observation of each patient. I. Introduction and design

Phase I trial of 13-cis-retinoic acid in children with neuroblastoma following bone marrow transplantation.

Treatment of high-risk neuroblastoma with intensive chemotherapy, radiotherapy, autologous bone marrow transplantation, and 13-cis-retinoic acid. Children's Cancer Group.

Revisions of the international criteria for neuroblastoma diagnosis, staging, and response to treatment.

High dose melphalan in the treatment of advanced neuroblastoma: results of a randomised trial (ENSG-1) by the European Neuroblastoma Study Group.

Myeloablative megatherapy with autologous stem-cell rescue versus oral maintenance chemotherapy as consolidation treatment in patients with high-risk neuroblastoma: a randomised controlled trial.

Retinoid therapy of high-risk neuroblastoma.

A randomized trial of 13-Cis retinoic acid in children with advanced neuroblastoma after high-dose therapy.

Bone marrow transplantation for neuroblastoma: a review of 509 cases. EBMT Group.

Prognostic factors in metastatic neuroblastoma in patients over 1 year of age treated with high-dose chemotherapy and stem cell transplantation: a multivariate analysis in 218 patients treated in a single institution.

P304

1007-1013

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P3181

1034162

http://www.w3.org/2001/XMLSchema#string

P356

10.1200/JCO.2007.13.8925

http://www.w3.org/2001/XMLSchema#string

P407

P433

7

http://www.w3.org/2001/XMLSchema#string

P478

27

http://www.w3.org/2001/XMLSchema#string

P50

P577

2009-01-26T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

19171716

http://www.w3.org/2001/XMLSchema#string

P932

2738615

http://www.w3.org/2001/XMLSchema#string